CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

Exclusion Criteria

• •Active infection not controlled with appropriate antimicrobial therapy
• •HIV, hepatitis B or C infection or known history of HIV, hepatitis B or C(all patients will be tested for HIV, hepatitis B and C as part of standard pre-transplant testing, and will be excluded from this trial if positive)
• •Anti-thymocyte globulin, or cyclophosphamide administered within 14 days before or planned to receive with HCT conditioning or as part of GVHD prophylaxis in the 14 days after HCT
• •Known allergic reactions to components of the study drug
• •Concurrent treatment with another investigational drug
• •History of thromboembolism, transient ischemic attack, stroke, myocardial infarction within 3 months preceding the transplant, or uncontrolled congestive heart failure or cardiac arrhythmias.